Acorda reaches settlement with Mylan on generic Ampyra

6 August 2018

In a filing with the Securities and Exchange Commission, US neurological diseases specialist Acorda Therapeutics (Nasdaq: ACOR) reported updates on its litigation with Netherlands-headquartered drugmaker Mylan (Nasdaq: MYL) and its affiliates, as well as other, relating to multiple sclerosis drug Ampyra (dalfampridine) Orange Book-listed patents.

As previously reported, the company awaits a decision of the US Court of Appeals for the Federal Circuit in the company’sappeal of a 2017 US District Court decision which invalidated four of the company’s Ampyra Orange Book-listed patents that were set toexpire between 2025 and 2027.

As a result of the settlement agreement, Mylan will be permitted to market its generic version of Ampyra in the US sometime in 2025 or earlier under certain circumstances.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK